Protox Initiates Phase 2 Prostate Cancer Study

13, 2008 /CNW/ - Protox Therapeutics Inc. (TSX: PRX), a leader in advancing novel, targeted therapeutic proteins, today announced that data from the completed Phase 1 clinical read testing PRX302 in patients. Vancouver, vitamin BC, January 30, 2008--Protox Therapeutics announced that it has received conditional approval after the listing of its everyday shares on the Toronto Stock Exchange.. VANCOUVER - Protox Therapeutics Inc. (TSXV:PRX) has reported a positive Phase 1 read on its PRX302 drug runner after benign prostatic hyperplasia, a everyday condition amidst aging males. Protox said Thursday that results from the proof . 3, 2008 (Canada NewsWire via COMTEX) -- Protox(TM: 106.61, +0.15, +0.14%) Therapeutics Inc. (TSX-V: PRX), a leader in advancing novel, targeted protein toxin therapeutics after the treatment of cancer and other proliferative diseases, . Protox Therapeutics has received institutional review board approvals to proceed with its Phase IIa clinical proof evaluating PRX302 after the treatment of localized recurrent prostate cancer. The compa. Vancouver, BC, January 30, 2008--Protox Therapeutics announced that it has received conditional approval after the listing of its everyday shares on the Toronto Stock Exchange.. Vancouver, BC, January 15, 2008--Protox Therapeutics today announced that the Company has received Institutional Review Board approvals to proceed with its Phase 2a clinical proof evaluating PRX302 after the treatment of localized . Vancouver, BC, January 30, 2008--Protox Therapeutics announced that it has received conditional approval after the listing of its everyday shares on the Toronto Stock Exchange.. VANCOUVER - Protox Therapeutics Inc. (TSXV:PRX) has reported a positive Phase 1 read on its PRX302 drug runner after benign prostatic hyperplasia, a everyday condition amidst aging males. Protox said Thursday that results from the proof .